Sofosbuvir in Treatment of COVID 19

Sofosbuvir Based Regimens in Treatment of COVID 19 Patients

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04460443

Enrollment

Registered

2020-07-07

Start date

2020-08-01

Completion date

2021-08-31

Last updated

2020-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID

Brief summary

Sofosbuvir containing treatment in treatment of COVID 19 Egyptian patients

Detailed description

Sofosbuvir containing treatment of COVID 19 Egyptian patients: a randomized-controlled trial

Interventions

DRUGsofosbuvir

Sofosbuvir once daily

DRUGSofosbuvir ledipsavir

Sofosbuvir ledipsavir once daily

DRUGDaclatasvir

Daklatasuvir tablets

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Covid positive patients.

Exclusion criteria

* Contraindication to sofosbuvir or ribavirin.

Design outcomes

Primary

Measure	Time frame	Description
Number of patients with response to treatment	1 month	The total number of patients with response to treatment

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, ass. prof.

sheriefabdelsalam@yahoo.com00201147773440

Backup Contactsherief abd-elsalan, ass. prof.